OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors	566
Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes	402
Translating IL-6 biology into effective treatments	361
Mechanisms and therapeutic implications of cellular senescence in osteoarthritis	283
Autoimmune and inflammatory diseases following COVID-19	281
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment	276
Synovial inflammation in osteoarthritis progression	248
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines	232
Global epidemiology of systemic lupus erythematosus	228
Emerging pharmaceutical therapies for osteoarthritis	206
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	189
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications	187
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	183
Systemic and organ-specific immune-related manifestations of COVID-19	182
IgG4-related disease: an update on pathophysiology and implications for clinical care	164
The gut–joint axis in rheumatoid arthritis	161
Kawasaki disease: pathophysiology and insights from mouse models	141
New insights into the role of antinuclear antibodies in systemic lupus erythematosus	141
Toll-like receptor signalling in B cells during systemic lupus erythematosus	140
COVID-19 revisiting inflammatory pathways of arthritis	138
Early-stage symptomatic osteoarthritis of the knee — time for action	135
A new immunometabolic perspective of intervertebral disc degeneration	133
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?	131
Immune-mediated necrotizing myopathy: clinical features and pathogenesis	128
Cell-based strategies for IVD repair: clinical progress and translational obstacles	125

Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	124
Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison	124
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis	121
Global epidemiology of vasculitis	118
Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis	118
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis	115
Combating physical inactivity during the COVID-19 pandemic	113
Rheumatic disease and COVID-19: epidemiology and outcomes	112
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis	105
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	105
Digital health technologies: opportunities and challenges in rheumatology	104
The non-coding RNA interactome in joint health and disease	103
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	102
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	101
Oral surveillance and JAK inhibitor safety: the theory of relativity	91
Interplay between genetics and epigenetics in osteoarthritis	90
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases	85
PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets	81
Fibroblast growth factor signalling in osteoarthritis and cartilage repair	78
TNF in the era of immune checkpoint inhibitors: friend or foe?	76
Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease	75
Immune cartography of macrophage activation syndrome in the COVID-19 era	74
Axial spondyloarthritis: concept, construct, classification and implications for therapy	74
The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic	73
The endothelium–bone axis in development, homeostasis and bone and joint disease	70
The evolution of nerve growth factor inhibition in clinical medicine	69
Sex steroids and autoimmune rheumatic diseases: state of the art	65
Location, location, location: how the tissue microenvironment affects inflammation in RA	65
Current and future therapies for primary Sjögren syndrome	64
Interleukin-2 and regulatory T cells in rheumatic diseases	59
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	57
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation	56
Treatment of axial spondyloarthritis: an update	56
Targeting interferon-γ in hyperinflammation: opportunities and challenges	56